Suppr超能文献

人表皮生长因子受体2(Her-2/neu)状态:印度乳腺癌患者预后及管理中被忽视的标志物

Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.

作者信息

Zubeda Syeda, Kaipa Prabhakar Rao, Shaik Noor Ahmad, Mohiuddin Mohammed Khaliq, Vaidya Sireesha, Pavani Boddana, Srinivasulu Mukta, Latha Manolla Madhavi, Hasan Qurratulain

机构信息

Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Andhra Pradesh, India.

出版信息

Asian Pac J Cancer Prev. 2013;14(4):2231-5. doi: 10.7314/apjcp.2013.14.4.2231.

Abstract

BACKGROUND

Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients.

MATERIALS AND METHODS

A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects.

RESULTS

In the present study, the ages ranged from 20-87 years with a mean of 50.0±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive.

CONCLUSIONS

ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.

摘要

背景

根据雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER/Neu 2)受体状态对乳腺肿瘤进行分类,对于预测乳腺癌的预后及辅助治疗十分必要。在此,我们对印度南部患者的这一问题进行了评估。

材料与方法

在获得伦理批准后,从病理档案中收集了619份福尔马林固定石蜡包埋的乳腺肿瘤组织。借助一抗和二抗共轭抗体,确定ER、PR和HER2/neu的表达状态。所有实验数据均评估与肿瘤组织病理学特征及受试者临床表现的相关性。

结果

在本研究中,患者年龄范围为20 - 87岁,平均年龄为50.0±12.q岁,大多数肿瘤(84%)为浸润性导管细胞癌类型。ER、PR和Her-2/neu表达评估显示,46%为三阴性。有趣的是,41.2%(p<0.0001)的肿瘤中ER、PR和HER-2/neu之间存在明显的负相关,其中24.5%(p<0.0001)为ER和PR均阴性但HER-2阳性。

结论

在印度乳腺癌患者中,ER和PR阳性肿瘤(即<30%)比HER-2/neu阳性肿瘤(即>50%)更少见,这凸显了在印度等资源匮乏国家需要有效的诊断筛查和特定的治疗管理措施,以提高患者的生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验